** Next Science NXS.AX slumps as much as 13% to record low of A$0.1; set for weakest trading session since October 2024
** Medical tech firm says a former employee filed litigation in the U.S., alleging breaches of fiduciary duties and mismanagement against several employees
** Litigation makes several claims - that certain tech has not been approved by U.S. FDA and that co did not take sufficient measures to address safety concerns about the use of its surgical solution in breast implant procedures
** Co says its products are safe, effective and FDA-approved
** Stock fell 66.2% in 2024
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((manasi.dasasundeep@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.